AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22972771 — intervention group
Group type: COMPARATOR
Intervention: Stress Management (SM)
Number of subjects: 391
Study 22972771 — intervention group
Group type: COMPARATOR
Intervention: Exercise (EX)
Number of subjects: 391
Study 22972771 — intervention group
Group type: COMPARATOR
Intervention: Stress Management and Exercise (SMEX)
Number of subjects: 391
Study 22972771 — intervention group
Group type: COMPARATOR
Intervention: Coping Confidence
Number of subjects: 391
Study 19079814 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ‐54 treatment (yokukansan) in period I
Number of subjects: 106
Study 19079814 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ‐54 treatment (yokukansan) in period II
Number of subjects: 106
Study 19079814 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ‐54 treatment in group A
Number of subjects: 106
Study 19079814 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ‐54 treatment in group B
Number of subjects: 106
Study 19079814 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ‐54 treatment
Number of subjects: 106
Study 19079814 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 106
Study 18085465 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2% ophthalmic solution (Pataday)
Number of subjects: 0
Study 18085465 — intervention group
Group type: COMPARATOR
Intervention: Olopatadine 0.1% ophthalmic solution (Patanol)
Number of subjects: 0
Study 18085465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16026692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus 5-FU/leucovorin (LV) for 6 months
Number of subjects: 801
Study 16026692 — intervention group
Group type: COMPARATOR
Intervention: Protracted venous infusion (PVI) 5-FU for 12 weeks
Number of subjects: 801
Study 16026692 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (Bolus 5-FU/LV and PVI 5-FU)
Number of subjects: 801
Study 16026692 — intervention group
Group type: COMPARATOR
Intervention: PVI 5-FU
Number of subjects: 801
Study 11920308 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir for 8 weeks
Number of subjects: 69
Study 11920308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 10357377 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly aggressive antiretroviral therapy (HAART)
Number of subjects: 28
Study 10357377 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) monotherapy
Number of subjects: 28
Study 10357377 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 28
Study 10357377 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination (ZDV, 3TC, SQV)
Number of subjects: 28
Study 10357377 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple combination (ZDV, 3TC, SQV, RTV)
Number of subjects: 28
Study 7573097 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-α (IFN-α) therapy at a dosage of 5 million units (MU)/m2 per day
Number of subjects: 0
Study 7573097 — intervention group
Group type: COMPARATOR
Intervention: Interferon-α (IFN-α) therapy
Number of subjects: 0
Study 7573097 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Interferon-α (IFN-α) and chemotherapy
Number of subjects: 0
Study 2149493 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 6 mg/kg
Number of subjects: 49
Study 2149493 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 12 mg/kg
Number of subjects: 49
Study 7381125 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol 0.65 mg (3 inhalations at 10 and 20 min)
Number of subjects: 19
Study 7381125 — intervention group
Group type: COMPARATOR
Intervention: Metaproterenol 1.95 mg (single inhalation)
Number of subjects: 19
Study 7381125 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 inhalations at 10 and 20 min)
Number of subjects: 19
Study 30859377 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus A9-eluting stent (2-link BES)
Number of subjects: 226
Study 30859377 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (3-link EES)
Number of subjects: 226
Study 30859377 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 226
Study 26936898 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate, high fat, and protein-permitted diet
Number of subjects: 126
Study 26936898 — intervention group
Group type: COMPARATOR
Intervention: Fasting for at least 12 hours
Number of subjects: 126
Study 25655763 — intervention group
Group type: EXPERIMENTAL
Intervention: PDI-Couple Interview (PDI-CI) delivered by a clinical psychologist
Number of subjects: 12
Study 25655763 — intervention group
Group type: EXPERIMENTAL
Intervention: PDI-Couple Interview (PDI-CI)
Number of subjects: 12
Study 23110580 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-SEAs (Futurabond M, Clearfil S3 Bond, Optibond All-in-One)
Number of subjects: 50
Study 23110580 — intervention group
Group type: COMPARATOR
Intervention: 2-ERA (Adper Single Bond 2/3M ESPE)
Number of subjects: 50
Study 21649633 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities adjusted to personality style of interest (PSI), n=33
Number of subjects: 128
Study 21649633 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities adjusted to functional level and personality style of interest (FL+PSI), n=31
Number of subjects: 128
Study 21649633 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities adjusted to functional level (FL), n=32
Number of subjects: 128
Study 21649633 — intervention group
Group type: COMPARATOR
Intervention: Active control (AC), n=32
Number of subjects: 128
Study 21649633 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (FL, PSI, FL+PSI)
Number of subjects: 128
Study 21649633 — intervention group
Group type: EXPERIMENTAL
Intervention: One week after intervention
Number of subjects: 128
Study 19454025 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified houses with ceilings of papyrus mats and insecticide-treated netting (ITN)
Number of subjects: 20
Study 19454025 — intervention group
Group type: COMPARATOR
Intervention: Unmodified houses (Control)
Number of subjects: 20
Study 19454025 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified houses with ceilings of papyrus mats and ITN
Number of subjects: 20
Study 18095197 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg gabapentin
Number of subjects: 45
Study 18095197 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg gabapentin
Number of subjects: 45
Study 18095197 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gabapentin)
Number of subjects: 45
Study 14555862 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg cumulative dose: 6.25 mg + 18.75 mg 1 h later)
Number of subjects: 216
Study 14555862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 14555862 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 216
Study 10866081 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 micromol/kg Gd-EOB-DTPA
Number of subjects: 35
Study 10866081 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micromol/kg Gd-EOB-DTPA
Number of subjects: 35
Study 10866081 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micromol/kg Gd-EOB-DTPA
Number of subjects: 35
Study 9199073 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cryotherapy (closed system)
Number of subjects: 312
Study 9199073 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cryotherapy (conventional cold packs)
Number of subjects: 312
Study 8482064 — intervention group
Group type: EXPERIMENTAL
Intervention: Metadoxine
Number of subjects: 60
Study 8482064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3885033 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillamine (1 g per day)
Number of subjects: 227
Study 3885033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 3885033 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 227
Study 30221864 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide treatment
Number of subjects: 29
Study 30221864 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 29
Study 27093773 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% w/w stannous fluoride dentifrice (test dentifrice)
Number of subjects: 351
Study 27093773 — intervention group
Group type: COMPARATOR
Intervention: Marketed standard fluoride dentifrice (negative control)
Number of subjects: 351
Study 24233343 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 synthetic long-peptide vaccine (HPV16-SLP)
Number of subjects: 0
Study 24233343 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination after 1 year with HPV16-SLP
Number of subjects: 0
Study 24233343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22893132 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition colonoscopes (EC-530 and EC-590) using Flexible Spectral Imaging Color Enhancement (FICE)
Number of subjects: 293
Study 22893132 — intervention group
Group type: COMPARATOR
Intervention: Standard-definition colonoscopes (EC-530) using Flexible Spectral Imaging Color Enhancement (FICE)
Number of subjects: 293
Study 22893132 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition colonoscopes (EC-530 and EC-590) using White Light Imaging (WLI)
Number of subjects: 293
Study 22893132 — intervention group
Group type: COMPARATOR
Intervention: Standard-definition colonoscopes (EC-530) using White Light Imaging (WLI)
Number of subjects: 293
Study 20825316 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen sponge
Number of subjects: 602
Study 20825316 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 602
Study 18432488 — intervention group
Group type: EXPERIMENTAL
Intervention: Study of theme-related items presented in nonword form
Number of subjects: 0
Study 18432488 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumbled words with difficult letter rearrangements
Number of subjects: 0
Study 18432488 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation durations ranging from 110 ms to 880 ms
Number of subjects: 0
Study 18432488 — intervention group
Group type: EXPERIMENTAL
Intervention: Study conditions conducive to recoding
Number of subjects: 0
Study 16201125 — intervention group
Group type: COMPARATOR
Intervention: Whipple procedure
Number of subjects: 36
Study 16201125 — intervention group
Group type: EXPERIMENTAL
Intervention: PPPD
Number of subjects: 36
Study 12907329 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 1370
Study 10388649 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine formulated into Iscom particles
Number of subjects: 100
Study 10388649 — intervention group
Group type: COMPARATOR
Intervention: Standard influenza vaccine
Number of subjects: 100
Study 9116931 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 degrees right anterior oblique (RAO) projection
Number of subjects: 206
Study 9116931 — intervention group
Group type: COMPARATOR
Intervention: 60 degrees left anterior oblique (LAO) projection
Number of subjects: 206
Study 1799472 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil (CB; 10 mg/day)
Number of subjects: 70
Study 1799472 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (CB) plus interferon alfa‐2b (5 million units (MU)/m2 subcutaneously three times a week)
Number of subjects: 70
Study 1799472 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b during the induction phase
Number of subjects: 70
Study 1799472 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with interferon alfa‐2b
Number of subjects: 70
Study 6152029 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 40
Study 6152029 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg
Number of subjects: 40
Study 6152029 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiomazine 25 mg
Number of subjects: 40
Study 6152029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31931269 — intervention group
Group type: COMPARATOR
Intervention: Implanted port catheters (PORTs)
Number of subjects: 256
Study 31931269 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripherally inserted central catheters (PICCs)
Number of subjects: 256
Study 29397092 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhus capsules
Number of subjects: 80
Study 29397092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27689547 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid + antiviral
Number of subjects: 50
Study 27689547 — intervention group
Group type: COMPARATOR
Intervention: Steroid
Number of subjects: 50
Study 24152667 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based case management intervention (monthly home visits by nurses and physiotherapists for 12 months)
Number of subjects: 153
Study 24152667 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 153
Study 24152667 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based case management intervention
Number of subjects: 153
Study 22215470 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-only intervention
Number of subjects: 808
Study 22215470 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-only intervention
Number of subjects: 808
Study 22215470 — intervention group
Group type: EXPERIMENTAL
Intervention: Family + Community intervention
Number of subjects: 808
Study 22215470 — intervention group
Group type: COMPARATOR
Intervention: Measurement-only condition
Number of subjects: 808
Study 20481635 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylon-3 copolymers with N-terminal octadecanoyl unit
Number of subjects: 0
Study 20481635 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylon-3 copolymers
Number of subjects: 0
Study 20481635 — intervention group
Group type: COMPARATOR
Intervention: Discrete peptides intended to mimic SP-B
Number of subjects: 0
Study 20481635 — intervention group
Group type: COMPARATOR
Intervention: Peptoid-based mimic
Number of subjects: 0
Study 18033323 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous for XRCC3 Thr241Met allele
Number of subjects: 452
Study 18033323 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide, daunomycin (therapy likely to generate DNA double-strand breaks)
Number of subjects: 452
Study 18033323 — intervention group
Group type: COMPARATOR
Intervention: Anti-metabolite therapy (fludarabine, cytarabine)
Number of subjects: 452
Study 18033323 — intervention group
Group type: COMPARATOR
Intervention: RAD51 G135C and GSTM1 deletion polymorphism
Number of subjects: 452
Study 15830989 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fat placement around the spinal root (group A)
Number of subjects: 74
Study 15830989 — intervention group
Group type: COMPARATOR
Intervention: No autologous fat placement (control group B)
Number of subjects: 74
Study 11828042 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with COPD
Number of subjects: 23
Study 11828042 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 23
Study 10426347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal configuration
Number of subjects: 200
Study 10426347 — intervention group
Group type: COMPARATOR
Intervention: Anodal configuration
Number of subjects: 200
Study 7731622 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulphate (i.v.)
Number of subjects: 60
Study 7731622 — intervention group
Group type: COMPARATOR
Intervention: CCK (i.v.)
Number of subjects: 60
Study 2103209 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 42
Study 2103209 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 42
Study 2103209 — intervention group
Group type: EXPERIMENTAL
Intervention: Xipamide
Number of subjects: 42
Study 2103209 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 42
Study 2103209 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LVH
Number of subjects: 42
Study 2103209 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 42
Study 6116296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg bd for four weeks
Number of subjects: 44
Study 6116296 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen 1 mg, 2 mg, and 4 mg before exercise
Number of subjects: 44
Study 6116296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 30850941 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicators of general health and economic deprivation
Number of subjects: 2501
Study 30850941 — intervention group
Group type: EXPERIMENTAL
Intervention: Each degree of deprivation
Number of subjects: 2501
Study 30850941 — intervention group
Group type: EXPERIMENTAL
Intervention: Households with two or more poverty indicators
Number of subjects: 2501
Study 28567691 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived stem cells (ASCs) at a dose of 1 × 10^7 cells/mL
Number of subjects: 15
Study 28567691 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived stem cells (ASCs) at a dose of 2 × 10^7 cells/mL
Number of subjects: 15
Study 28567691 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived stem cells (ASCs)
Number of subjects: 15
Study 28567691 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 15
Study 26579572 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg in the morning) and placebo (in the evening) for 24 weeks
Number of subjects: 64
Study 26579572 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg in the morning) and melatonin (5 mg in the evening) for 24 weeks
Number of subjects: 64
Study 23713815 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control strategy for treatment of AF
Number of subjects: 265
Study 23713815 — intervention group
Group type: COMPARATOR
Intervention: Rhythm control strategy for treatment of AF
Number of subjects: 265
Study 23713815 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher tertile MPV group (≥7.9 fL)
Number of subjects: 265
Study 23713815 — intervention group
Group type: EXPERIMENTAL
Intervention: MPV cut-off level set to 7.85 fL
Number of subjects: 265
Study 23713815 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control strategy with high MPV (>7.85 fL) and high CHADS2 score
Number of subjects: 265
Study 21676011 — intervention group
Group type: COMPARATOR
Intervention: XEN-D0501 1 mg twice daily
Number of subjects: 36
Study 21676011 — intervention group
Group type: COMPARATOR
Intervention: XEN-D0501 2.5 mg twice daily
Number of subjects: 36
Study 21676011 — intervention group
Group type: COMPARATOR
Intervention: XEN-D0501 5 mg twice daily
Number of subjects: 36
Study 21676011 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN-D0501 5 mg single dose (fasted and fed conditions)
Number of subjects: 36
Study 21676011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19765496 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced podcast (based on social cognitive theory)
Number of subjects: 78
Study 19765496 — intervention group
Group type: COMPARATOR
Intervention: Control podcast
Number of subjects: 78
Study 17205438 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin (1 g)
Number of subjects: 156
Study 17205438 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day azithromycin (500 mg daily)
Number of subjects: 156
Study 17205438 — intervention group
Group type: COMPARATOR
Intervention: 3-day levofloxacin (500 mg daily)
Number of subjects: 156
Study 17205438 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin-based regimens (single-dose and 3-day)
Number of subjects: 156
Study 15601351 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine + 5 microg x ml(‐1) fentanyl
Number of subjects: 31
Study 15601351 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine + 5 microg x ml(‐1) fentanyl
Number of subjects: 31
Study 15601351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 31
Study 11235719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac ischemic preconditioning (group IP): two cycles of 3 minutes of aortic cross‐clamping and 2 minutes of reperfusion before cardioplegic arrest
Number of subjects: 40
Study 11235719 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C): 10 minutes of cardiopulmonary bypass
Number of subjects: 40
Study 10986367 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaningful labels (creative or non-creative)
Number of subjects: 0
Study 10986367 — intervention group
Group type: COMPARATOR
Intervention: Meaningless labels (group 1 or group 2)
Number of subjects: 0
Study 10986367 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlimited time to respond
Number of subjects: 0
Study 10986367 — intervention group
Group type: COMPARATOR
Intervention: Forced to respond quickly
Number of subjects: 0
Study 9127169 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide, 40 micrograms/h, by continuous i.v. infusion for 5 days
Number of subjects: 58
Study 9127169 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to standard supportive therapy
Number of subjects: 58
Study 9127169 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide group
Number of subjects: 58
Study 9127169 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 58
Study 1492864 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mg DHEC oral vial once daily for 3 months
Number of subjects: 240
Study 1492864 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mg DHEC tablet once daily for 3 months
Number of subjects: 240
Study 1492864 — intervention group
Group type: COMPARATOR
Intervention: Placebo vial once daily for 3 months
Number of subjects: 240
Study 1492864 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet once daily for 3 months
Number of subjects: 240
Study 3891920 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at a pressure of two atmospheres absolute
Number of subjects: 0
Study 3891920 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 31228760 — intervention group
Group type: EXPERIMENTAL
Intervention: AFS (fentanyl bolus ± infusions)
Number of subjects: 90